The proportions of CD11b+CD33+CD14-HLADR- (Gr-MDSCs) and CD14+HLADR- (Mo-MDSCs) cells in the PB of CML patients at diagnosis and during IM therapy were evaluated using flow cytometry. The gene discussed is CD14; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.